title: Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
abstract: BACKGROUND
  The Treatment Satisfaction Questionnaire for Medication (TSQM) was designed to assess patient treatment satisfaction in chronic diseases. Its performance has not been examined in multiple sclerosis (MS). The 14 items of the TSQM cover four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction.
  
  
  OBJECTIVE
  To evaluate performance of the TSQM in patients with relapsing MS, using data collected from the TENERE study (NCT00883337), in which 324 patients received oral teriflunomide or subcutaneous interferon beta-1a for ⩾48 weeks.
  
  
  METHODS
  Five measurement properties were examined using traditional psychometric methods: data completeness, scale-to-sample targeting, scaling assumptions, reliability (including test-retest), and construct validity (internal: item-level scaling success, confirmatory factor analysis, and exploratory factor analysis; external: convergence, discrimination, and group differences).
  
  
  RESULTS
  There were few (<2%) missing item data; domain scores could be computed for all patients. Score distributions were skewed toward higher satisfaction; two domains had marked ceiling effects. Scaling assumptions were supported. Internal consistency reliability was high (Cronbach's α > 0.90). Internal validity tests supported item groupings. Correlations supported convergent and discriminant construct validity; hypothesis testing supported group differences validity.
  
  
  CONCLUSIONS
  This investigation found the TSQM to be a useful tool, exhibiting good psychometric measurement properties in patients with relapsing MS in the TENERE study.
authors.affiliation: Department of Neurology, University of Lille, Lille, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Vermersch
authors.affiliation: Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Hobart
authors.affiliation: Sanofi Genzyme, Chilly-Mazarin, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Dive-Pouletty
authors.affiliation: Sanofi Genzyme, Chilly-Mazarin, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bozzi
authors.affiliation: Sanofi Genzyme, Cambridge, MA, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Hass
authors.affiliation: Stony Brook University, Stony Brook, NY, USA.
authors.forename: Patricia K
authors.initials: PK
authors.lastname: Coyle
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D010549:Personal Satisfaction; D011594:Psychometrics / Q000379:methods; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires
keywords: Multiple sclerosis; disease-modifying therapy; outcomes assessment; psychometrics; relapsing-remitting; teriflunomide; treatment satisfaction